B+
Bull case
20%
Probability
Target price
$1.45
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
COCP
CocrystalFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
CDI-988 is advancing through a human-challenge Phase 1b study, has Fast Track designation, and could generate a meaningful re-rating if clinical data are positive. The influenza SBIR award provides non-dilutive support but is secondary to CDI-988.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Development-stage financing and potential dilution remain material risks for a roughly $11 million biotechnology company.
Momentum
83
Value
41
Sentiment
10
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.65 · Bull $1.45 · Bear $0.35Analysis 2026-07-31; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-31 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $8.00
Why
Momentum83 · Δ7d -
Value41 · Δ7d -0.0
Sentiment10 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • Development-stage financing and potential dilution remain material risks for a roughly $11 million biotechnology company.
- • Leadership transition and execution risk increased following the June 2026 CEO appointment [#SEC-8K-2026-06-03].
- • The company remains a low-coverage microcap biotech with binary clinical risk, no disclosed data-readout date, and limited evidence of near-term revenue or commercialization.
Catalyst clock
2026-10-29
CDI-988 Phase 1b challenge-study data
Lead driver: Value · See fundamentals
Momentum
83
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
10
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 83.2 / Value 41.2 / Sentiment 10.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-07-31. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$0.65
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.35
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$21M
Beta
1.19
Shares Out
13.79M
P/E (TTM) · Derived
-1.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.93
Rev YoY
-100.0%
EPS YoY
+13.6%
Gross Margin
+37.3%
Op Margin
-
Net Debt
-$5.6M
Current Ratio
1.24
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data